4th Quarter - Report

ALEXION PHARMACEUTICALS, INC. for ALEXION PHARMACEUTICALS, INC.

Firm
Client
Income
—
Expenses
$275,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Comprehensive Tax Reform proposals Patent Box proposals Orphan Drug Tax Credit R&D Tax Credit

LobbyistCovered position, as disclosed
VANESSA PROCTER —
HEIDI L WAGNER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

ACA Implementation issues, including health exchanges, biosimilars Track & Trace; pharmaceutical compounding Implementation legislation 340B issues Budget/Sequester issues impacting Medicare/Medicaid (SGR) and FDA user fees

LobbyistCovered position, as disclosed
VANESSA PROCTER —
HEIDI L WAGNER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.